Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma

被引:1
|
作者
Todoroki, Keita [1 ,2 ]
Abe, Yushi [1 ,2 ]
Matsuo, Katsuhisa [1 ,2 ]
Nomura, Hidetoshi [1 ]
Kawahara, Akihiko [3 ]
Nakamura, Yoshiaki [4 ]
Nakamura, Moriyoshi [1 ]
Seki, Naoko [1 ]
Kusukawa, Jingo [1 ]
机构
[1] Kurume Univ, Dent & Oral Med Ctr, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan
[2] Kouhoukai Med Corp, Takagi Hosp, Dept Dent & Oral Surg, Okawa, Fukuoka 8310016, Japan
[3] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka 8300011, Japan
[4] Oita Saiseikai Hita Hosp, Dept Dent & Oral Surg, Hita, Oita 8771292, Japan
关键词
CSC; OSCC; CD44v3; CD24; programmed cell death ligand 1; programmed cell death 1; immune checkpoint inhibitors; HEAD; PD-L1; CD24; IDENTIFICATION; IMMUNOTHERAPY; POPULATION; RECURRENT;
D O I
10.3892/ol.2024.14213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between cancer stem cells (CSCs) in oral squamous cell carcinoma (OSCC) and programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) remains unclear. Therefore, the present study aimed to clarify the association between the CD44v3(high)/CD24(low) immunophenotype of CSCs in OSCC and PD-L1/PD-1 co-expression, and to assess the prognostic effect of CSCs in terms of immune checkpoint molecules. Formalin-fixed, paraffin-embedded tissue samples and clinicopathological data from 168 patients with OSCC were retrospectively retrieved. Immunohistochemical staining and reverse transcription quantitative polymerase chain reaction were applied to a tissue microarray of the invasive front of each case. Semi-automated cell counting was used to assess CD44v3, CD24, PD-L1 and PD-1 expression by immunohistochemistry (IHC) using a digital image analysis program. Associations between immunological markers and clinicopathological variables were estimated. Patients with the CSC immunophenotype CD44v3(high)/CD24(low), and patients with a high PD-L1/PD-1-positive cell density in the tumor parenchyma and stroma had significantly lower survival rates. Furthermore, patients with the CSC immunophenotype (CD44v3(high)/CD24(low)) and high PD-L1/PD-1 co-expression had even lower survival rates (P<0.01, log-rank test). Notably, there was a positive correlation between CD44v3 and PD-L1 expression (tau=0.1096, P=0.0366, Kendall rank correlation coefficient) and a negative correlation between CD24 and PD-1 expression (tau=-0.1387, P=0.0089, Kendall rank correlation coefficient). Additionally, the high CD44v3 expression group, as determined by IHC, exhibited significantly decreased expression of U2 small nuclear RNA auxiliary factor 1 (U2AF1) at the mRNA level compared with that in the low CD44v3 expression group (P<0.001, Mann-Whitney U test), and U2AF1 and PD-L1 mRNA expression exhibited a significant negative correlation (tau=-0.3948, P<0.001, Kendall rank correlation coefficient). In conclusion, CSCs in OSCC may evade host immune mechanisms and maintain CSC stemness via PD-L1/PD-1 co-expression, resulting in unfavorable clinical outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications
    Wolkow, Natalie
    Jakobiec, Frederick A.
    Afrogheh, Amir H.
    Eagle, Ralph C., Jr.
    Pai, Sara, I
    Faquin, William C.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2019, 200 : 226 - 241
  • [2] Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype
    Satgunaseelan, Laveniya
    Gupta, Ruta
    Madore, Jason
    Chia, Noel
    Lum, Trina
    Palme, Carsten E.
    Boyer, Michael
    Scolyer, Richard A.
    Clark, Jonathan R.
    PATHOLOGY, 2016, 48 (06) : 574 - 580
  • [3] Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
    Chen, Kaiyan
    Cheng, Guoping
    Zhang, Fanrong
    Zhang, Nan
    Li, Dan
    Jin, Jiaoyue
    Wu, Junzhou
    Ying, Lisha
    Mao, Weimin
    Su, Dan
    ONCOTARGET, 2016, 7 (21) : 30772 - 30780
  • [4] Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts
    Yu, Wesley Y.
    Berger, Timothy G.
    North, Jeffrey P.
    Laszik, Zoltan
    Cohen, Jarish N.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (05) : 1127 - 1133
  • [5] Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma
    Cui, Yong-Xin
    Su, Xian-Shuang
    OPEN MEDICINE, 2020, 15 (01): : 292 - 301
  • [6] Programmed Cell Death Ligand 1 Expression in Canine Cancer
    Shosu, Kazuha
    Sakurai, Masashi
    Inoue, Kumi
    Nakagawa, Takayuki
    Sakai, Hiroki
    Morimoto, Masahiro
    Okuda, Masaru
    Noguchi, Shunsuke
    Mizuno, Takuya
    IN VIVO, 2016, 30 (03): : 195 - 204
  • [7] Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients
    Wang, Shuo
    Qu, Xiujuan
    Li, Zhi
    Che, Xiaofang
    Cao, Lili
    Yang, Xianghong
    Hu, Xuejun
    Xu, Ling
    Hou, Kezuo
    Fan, Yibo
    Wen, Ti
    Liu, Yunpeng
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (05)
  • [8] Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis
    Quan, Hongzhi
    Liu, Sixuan
    Shan, Zhongyan
    Liu, Ziyi
    Chen, Tianjun
    Hu, Yanjia
    Yao, Zhigang
    Fang, Liangjuan
    ARCHIVES OF ORAL BIOLOGY, 2020, 119
  • [9] Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma
    Lee, Kyu Sang
    Lee, Kyoungyul
    Yun, Sumi
    Moon, Seyoung
    Park, Yujun
    Han, Jung Ho
    Kim, Chae-Yong
    Lee, Hye Seung
    Choe, Gheeyoung
    JOURNAL OF NEURO-ONCOLOGY, 2018, 136 (03) : 453 - 461
  • [10] Programmed cell death 1 ligand 1 signals in cancer cells
    Kornepati, Anand V. R.
    Vadlamudi, Ratna K.
    Curie, TylerJ
    NATURE REVIEWS CANCER, 2022, 22 (03) : 174 - 189